{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:03:02Z","timestamp":1773183782371,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejpb.2025.114971","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T22:42:18Z","timestamp":1766356938000},"page":"114971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reflection paper on the APV workshop on in vitro performance testing of topically applied and topically acting substances"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-4035","authenticated-orcid":false,"given":"Dominique","family":"Lunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Gorissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3435-0186","authenticated-orcid":false,"given":"Michael","family":"Herbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hukauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-9192","authenticated-orcid":false,"given":"Adina","family":"Eichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114971_b0005","unstructured":"European Medicines Agency, Guideline on quality and equivalence of locally applied, locally acting cutaneous products, in EMA\/CHMP\/QWP\/708282\/2018. 2024."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114971_b0010","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/17425247.2016.1140146","article-title":"Drug crystallization \u2013 implications for topical and transdermal delivery","volume":"13","author":"Hadgraft","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"11","key":"10.1016\/j.ejpb.2025.114971_b0015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11095-020-02911-y","article-title":"Diving into batch-to-batch variability of topical products-a regulatory Bottleneck","volume":"37","author":"Miranda","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114971_b0020","doi-asserted-by":"crossref","unstructured":"A. Garc\u00eda-Arieta, J. Gordon, L. Gwaza, V. Merino, and V. Mangas-Sanjuan, Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union. Pharmaceutics, 2023. 15(2). 10.3390\/pharmaceutics15020601.","DOI":"10.3390\/pharmaceutics15020601"},{"issue":"7","key":"10.1016\/j.ejpb.2025.114971_b0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/pharmaceutics12070647","article-title":"Progressing towards the sustainable development of cream formulations","volume":"12","author":"Sim\u00f5es","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114971_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106726","article-title":"Equivalence assessment of creams with quali-quantitative differences in light of the EMA and FDA regulatory framework","volume":"195","author":"Volont\u00e8","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114971_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13050710","article-title":"The implications of regulatory framework for topical semisolid drug products: from critical quality and performance attributes towards establishing bioequivalence","volume":"13","author":"Ilic","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ejpb.2025.114971_b0040","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-024-03772-5","article-title":"Impact of different packaging configurations on a topical cream product","volume":"41","author":"Mohammed","year":"2024","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114971_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2016.08.010","article-title":"Film-forming formulations containing porous silica for the sustained delivery of actives to the skin","volume":"108","author":"Heck","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"18","key":"10.1016\/j.ejpb.2025.114971_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25184222","article-title":"A new method for in-situ skin penetration analysis by confocal raman microscopy","volume":"25","author":"Krombholz","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2025.114971_b0055","unstructured":"European Pharmacopeia (Ph. Eur.), Monography hydroxypropyl methylcellulose, in 0348. 2025."},{"key":"10.1016\/j.ejpb.2025.114971_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125214","article-title":"Investigation of the suitability of confocal Raman spectroscopy for the demonstration of bioequivalence of topical products","author":"Gaiser","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114971_b0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ics.12775","article-title":"Ex vivo-In vivo correlation of retinol stratum corneum penetration studies by confocal Raman microspectroscopy and tape stripping","volume":"44","author":"Krombholz","year":"2022","journal-title":"Int. J. Cosmet. Sci."},{"key":"10.1016\/j.ejpb.2025.114971_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114891","article-title":"A pivotal, dermal, in-vivo bioequivalence study performed by confocal Raman spectroscopy (CRS)","volume":"217","author":"Link","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114971_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106827","article-title":"Cutaneous pharmacokinetics-based bioequivalence: a clinical dermal open flow microperfusion verification study using lidocaine and prilocaine combination topical products","volume":"200","author":"Tiffner","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114971_b0080","unstructured":"European Medicines Agency, Guideline on the investigation of bioequivalence, in CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr **. 2010, EMA - European Medicines Agency."},{"key":"10.1016\/j.ejpb.2025.114971_b0085","unstructured":"U.S. Food and Drug Administration, In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs, in FDA-2022-D-1862. 2022."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114971_b0090","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.tiv.2008.01.009","article-title":"Inter- and intra-individual variability in human skin barrier function: a large scale retrospective study","volume":"22","author":"Meidan","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejpb.2025.114971_b0095","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-024-01222-z","article-title":"Discussion of EMA draft guideline on quality and equivalence of topical products based on comparison of approved mometasone furoate drugs","author":"Eichner","year":"2024","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejpb.2025.114971_b0100","unstructured":"Committee for Medicinal Products for Human Use (Chmp). Overview of comments received on \u2018Draft guideline on quality and equivalence of topical products\u2018. 2024; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/comments\/overview-comments-received-draft-guideline-quality-equivalence-topical-products-ema-chmp-qwp-708282-2018_en.pdf."},{"key":"10.1016\/j.ejpb.2025.114971_b0105","unstructured":"European Medicines Agency. Innovation Task Force briefing meetings. 2025; Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/innovation-task-force-briefing-meetings."}],"updated-by":[{"DOI":"10.1016\/j.ejpb.2026.115023","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000}},{"DOI":"10.1016\/j.ejpb.2026.115023","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000}}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125003492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125003492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:33:10Z","timestamp":1768926790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125003492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"alternative-id":["S0939641125003492"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114971","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reflection paper on the APV workshop on in vitro performance testing of topically applied and topically acting substances","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114971"}}